hotspot -WSS

hotspot

author：Wikipedia 2025-09-06 01:58:11 - browse：21

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Medicare innovation center doesn’t save money, experts say

focus

entertainment

Wikipedia

WSS

Flu, Covid vaccination rates decline, new survey data show

Will an HIV vaccine ever be a reality?

The stability of $0 premiums in Medicare Advantage

New oral drug delivery patch is modeled after octopus tentacles

A new study asks: Are we harming blood donors by taking blood?

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

knowledge

hotspot

entertainment

Psychedelics group wrestles with new pharma identity

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Continuity nursing helped my family in our darkest PICU moments

Inside the fall of star MIT scientist David Sabatini

The cancer drug shortage isn’t new — and neither are the solutions

Grail is spending more than ever lobbying Congress

Supreme Court strikes down use of affirmative action

Stop Congress from blocking public access to science

Continuity nursing helped my family in our darkest PICU moments

Nobel honors Karikó and Weissman's enduring partnership

focus

PhRMA sues HHS over Medicare drug price negotiation

Some top drug companies are starting to take action on climate

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

New oral drug delivery patch is modeled after octopus tentacles

Will an HIV vaccine ever be a reality?

Make 'food is medicine' a key part of White House nutrition meeting

focus

entertainment

Wikipedia

hotspot